In these cases RARa is fused to the PLZF, NPM, NuMA and STAT5b genes, respectively. Patients with fusion genes involving NPM and NuMA appear to be sensitive to ATRA, like patients with PML-RARa rearrangement. 1, 4 In contrast, APL with a PLFZ-RARa rearrangement lack differentiation response to retinoids, and the patients treated with ATRA alone have a poor prognosis. 1 The t(5;17) translocation is a very rare variant and leads to the NPM-RARa fusion protein and the reciprocal RARa-NPM protein.
5 NPM (nucleophosmin) is a nucleolar phosphoprotein that plays a role in ribosomal RNA assembly; it also has chaperoning activities, as well as nuclease activity. Recently, it has been found to associate with centrosomes, and possibly plays a role in the regulation of centrosomal duplication. 6 NPM-RARa protein has been shown to act as ligand-dependent transcriptional activator. 7 The patient, a 29-year-old man, was referred to our institute with pelvic granulocytic sarcoma. A white blood count was 2.9 Â 10 9 /l, with 78% neutrophils, 11% lymphocytes, 1% monocytes, 6% metamyelocytes and 4% myelocytes. Hemoglobin was 8.3 g/dl and platelets were 101 Â 10 9 /l. Bone marrow was hypercellular showing 90% promyelocytes. Auer rods were not detected. Immunophenotyping was positive for CD13, CD33 and MPO7.
Cytogenetic analysis were performed on short-term cultures from bone marrow samples and showed the following karyotype: 46,XY,t(5;17)(q35;q21) in 23 metaphases and 46,XY in four metaphases. Dual-color FISH was performed using the commercially available LSI PML/RARA Dual-color DNA probe (Vysis Inc.). The LSI PML probe is approximately 180 kb and hybridizes to chromosome 15q22 and the LSI RARA probe that hybridizes to chromosome 17q12 is approximately 400 kb in size. Probes were applied and detected according to manufacturer's instructions. In all, 100 nuclei/cells were analyzed. FISH analysis revealed metaphases with red signals (PML probe) on the normal chromosomes 15 and 1 green signal (RARa probe) on the normal chromosome 17 and the other one on chromosome 5, confirming translocation of RARa gene from chromosome 17 to 5.
NPM-RARa and RARa-NPM fusion transcripts were amplified in two ways. For NPM-RARa, we used NPM-ext (5 0 -GGAAGATT CGATGGACATGG-3 0 ) and RAR-B (5 0 -GCTTGTAGATGCGGG GTAGA-3 0 ) for the first round and NPM-int (5 0 -TCGGTTGTGAA CTAAAGGCC-3 0 ) with RAR-D (5 0 -CTGCTGCTCTGGGTCTCA AT-3 0 ) for the second round. For RARa-NPM, we used RAR-A (5 0 -TGCCTCCCTACGCCTTCTT-3 0 ) and NPM-Rext (5 0 -TCTGTG GAACCTTGCTACCA-3 0 ), and RAR-C (5 0 -TCTCCAGCACCAGCT TCCAG-3 0 ) with NPM-Rint (5 0 -TGACTCTGCATCTTCCTCCA-3 0 ) for the first and second round, respectively. The bands were purified from the agarose gel, and 100 ng of purified DNA were sequenced using the same specific primers as above and Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems). Using RT-PCR and sequencing of purified PCR products, we confirmed the involvement of NPM and RARa genes in the t(5;17)(q35;q21). We were able to find the NPM-RARa fusion transcript, but not RARa-NPM. Two alternatively spliced transcripts of NPM-RARa were expressed, respectively of 319 and 223 bp ( to nucleotide 357) in the two isoforms. The NPM junction, in the long isoform (319 bp) was found to be identical with the NPM junction sequence in NPM-RARa short isoform of the Redner case. 5 Only this long form of NPM-RARa was in the reading frame and was able to generate a translation product (Figure 2) . A total of four cases with balanced t(5;17) translocation have been identified: two were 12-year-old males and two were 2 1 2 À and 9-year-old females, therefore our patient is the first t(5;17) case described not of pediatric age. Moreover, the present case referred to our institution with pelvic granulocytic sarcoma, who regressed during therapy. Bone marrow was hypercellular with a high amount of promyelocytes with hypergranular cytoplasm and absence of Auer rods, as described in the previous patients. [1] [2] [3] 8 RT-PCR demonstrated expression of NPM-RARa in all cases, while the reciprocal RARa-NPM fusion was identified only in three patients 1, 3, 8 (Figure 2 ). The first report of a patient with t(5;17) described expression of two NPM-RARa isoforms, presumably as a result of alternative splicing. Both forms act as transcriptional activators, and, by analogy to PML-RARa, play a crucial role in leukemogenesis. 7 The three subsequent case reports indicated expression of only the shorter NPM-RARa transcript. 1, 2, 8 In contrast to three of the previous cases described, 1, 3, 8 our case showed positive RT-PCR only for NPM-RARa, but not for the reciprocal RARa-NPM transcript. Similar to the Redner's 5 report we identified two NPM-RARa isoforms, presumably derived from alternative splicing. PMLRARa, like the two NPM-RARa fusion proteins, retains the RARa DNA binding, dimerization and ligand-binding domains. 5 For this reason PML-RARa can interact with RARE sequences and can activate transcription from RARE reporter constructs in a ligand-dependent fashion. 5, 8 PML-RARa binds to RAREs and recruits a corepressor complex containing the nuclear corepressor N-CoR, Sin3 and histone deacetylase (HDAC1). 7 Unlike wild-type RARa that binds the corepressor complex only in the absence of retinoic acid, PML-RARa continues to bind the corepressor complex even in the presence of physiological levels of retinoic acid, and releases the corepressor only at pharmacological levels of retinoic acid. Moreover, PML-RARa binds the RARa heterodimerization partner RXR. By competing for free RXR, PML-RARa might inhibit the function of unrearranged RARa. 
Figure 2
Schematic diagram of NPM-RARa cDNAs. Two fusion transcripts, NPM S -RARa and NPM L -RARa, were identified by Redner et al. 5 They differ by 129 bases, 50 bases of NPM followed by 79 bases of sequence that bear no homology to sequences in the GenBank or EMBL databases. NPM S -RARa was identified also in the other three cases. 1, 2, 8 In the present case, we identified two fusion transcripts, NPM-RARa and NPM S -RARa, that differ by 94 bases.
Redner et al 7 demonstrated that both NPM-RARa fusion proteins act as ligand-dependent transcriptional activators of a series of retinoic acid-responsive reporter constructs, differing from wild-type RARa in a fashion that is both promoter and celltype dependent and showed that both forms interact with DNA as either homodimers or as RXR heterodimers. In addition NPMRARa proteins interact with coactivator and corepressor proteins in a manner similar to PML-RARa. The two isoforms identified by Redner et al, 5 NPM L -RARa and NPM S -RARa, differ by 129 bases: an additional 50 bases of NPM followed by 79 bases of sequence that bear no homology to sequences in the GenBank or EMBL databases. NPM S -RARa and NPM L -RARa fuse NPM and RARa coding sequences in the same reading frame to generate predicted translation products of 520 and 563 amino acids, respectively. NPM has four functional motifs: a putative metal binding site, a phosphorylation site, and two large acidic loops. 5 The acidic loops are deleted in the NPM-RARa fusion proteins, the phosphorylation site is maintained in NPM L -RARa but deleted in NPM S -RARa. Joined to the N-terminal elements of NPM in both NPM-RARa proteins are the RARa DNA binding, heterodimerization and ligand binding domains. In contrast, in our case the two isoforms of NPM-RARa differ by 94 nucleotides and sequencing of both fusion transcripts revealed that longer NPM-RARa is the same transcript identified in all the other cases presenting t(5;17) translocation, and shorter NPM-RARa lacks of 94 nucleotides of NPM upstream to the junction with RARa sequence. These data suggest that the sequences of NPM-RARa transcripts identified in our study do not retain the same reading frame and only the long form is able to generate a translation product (Figure 2) .
Regarding ATRA treatment 'in vivo', it was difficult to establish whether ATRA induces clinical responses in the patients previously described. In the first patient, 3 a 2 1 2 -yearold female, the response to retinoic acid is not clear enough to interpret, because the patient was treated with ATRA while in partial remission and relapsed within 2 weeks of cessation of ATRA. Hummel et al 8 presented a case of a 12-year-old male, who was treated in induction and consolidation chemotherapy with daunorubicin, Ara-C, 6-thioguanine, etoposide and dexamethasone; after 5 months relapse occurred and reinduction of remission was obtained with the therapy of Ara-C and ATRA, followed by allogenic BM transplantation. The response to ATRA was difficult to assess since Ara-C was part of reinduction treatment. A 9-year-old female, 1 was treated with ATRA as a part of induction therapy and was alive in first CR at 29 months. The last patient was a 12-year-old boy 2 who presented with severe DIC and died of cerebral hemorrhage after only 5 days of ATRA treatment.
Our patient obtained morphological and cytogenetic remission after the first consolidation cycle of therapy with idarubicin, Ara-C and ATRA, while the molecular remission was reached after another three cycles of therapy including idarubicin, mithoxantrone, etoposide, 6-thioguanine and ATRA. But after 22 months from diagnosis, the morphological, clinical and cytogenetic relapse occurred. However, there is evidence to indicate that the t(5;17) blasts can terminally differentiate 'in vitro' after short-term cultures with retinoic acid, in only one reported case. 4 Even though the t(5;17) variant has only been identified in a minority of APL patients, it represents a distinct subtype of APL with molecular, morphological and clinical features.
